Clinical Trials in Cleveland

Showing 6621-6640 of 19,775 trials

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

NCT05312801

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

Luminary Therapeutics20 participantsStarted Nov 2023

Cleveland, Ohio, United States • Cleveland, Ohio, United States

RECRUITINGPhase 1< 1 mile

LMY-920 for Treatment of Relapsed or Refractory Myeloma

NCT05546723

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.

Multiple Myeloma, RefractoryMultiple Myeloma in Relapse

Luminary Therapeutics30 participantsStarted Mar 2024

Cleveland, Ohio, United States

COMPLETED< 1 mile

Hypotension Prediction Index Study (HPI Study)

NCT03805217

A prospective, single-arm, open-label, multicenter post-approval study to determine whether the use of the Acumen HPI Software to guide intraoperative hemodynamic management in non-cardiac surgery reduces the duration of intraoperative hypotension below a threshold of Mean Arterial Pressure (MAP)

Hypotension

Edwards Lifesciences485 participantsStarted May 2019

Stanford, California, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +8 more locations

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

LMY-920 for Treatment of Relapsed or Refractory Myeloma

Hypotension Prediction Index Study (HPI Study)

Find Trials by Condition in Cleveland

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

Comparative Effectiveness of Direct Admission & Admission Through Emergency Departments for Children

Study to Compare the Use of a Behavioral Health App Versus Care As Usual for 16-22 Year Olds with Depression

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Stockholm3 Validation Study in a Multi-Ethnic Cohort

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Assessment of Macrophage Activation syndromE in STill's Disease

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients

Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth